Clinical Trials Logo
  1. Home
  2. Cancer of Stomach
  3. NCT05747482
  4. Details
NCT05747482 Clinical Trial

Omentectomy vs Omental Preservation in Resectable Cancer

Cancer of Stomach Clinical Trial

Official title:
Non-inferiority Randomized Clinical Trial Comparing Omenectomy and Omental Preservation in Resectable Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05747482
Other study ID # SMontmany2022
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date July 1, 2031

Study information
Verified date February 2023
Source Corporacion Parc Tauli
Contact Sandra Montmany, PhD
Phone 937231010
Email smontmany@tauli.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

European clinical guidelines do not establish a clear recommendation neither for nor against omentectomy of this segment, the American clinical guidelines recommend omentectomy in view of its potential long-term oncological benefit, and Japanese clinical guidelines only recommend 2nd segment omentectomy in locally advanced gastric cancers (stage T3-T4) recommending omental preservation in early gastric cancers (stage T1-T2). Faced with this lack of consensus, we propose a randomized, prospective and multicentric study in patients with resectable gastric cancer in stage T3-4 N+/- M0. Patients will be randomized into two groups, one where omentectomy of the 2nd omental portion will be performed and another where omental preservation will be performed. The aim of our study is to analyze the disease-free interval and survival between both groups, also comparing postoperative complications and mortality.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 569
Est. completion date July 1, 2031
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Older than 18 years old - Resectable gastric cancer - Gastric cancer T3-4 N+/- M0 Exclusion Criteria: - M1 - Non surgical patients for medical status - Non resectable gastric cancer during surgery - Endoscopic resectable gastric cancer

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Surgery procedure
Omentectomy vs omental preservations during gastric surgery

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Corporacion Parc Tauli

Outcome
Type Measure Description Time frame Safety issue
Primary disease free interval time between surgery and recurrence. Units of measure: months 5 years
Secondary global survival survival between surgery and last follow-up date. Units of measure: percentage 5 years
Secondary survival at 5 years survival between surgery and 5 years. Units of measure: percentage 5 years
Secondary complications - CCI type of complications and CCI number. Units of measure: enter number between 1 and 100 30 days after surgery
Secondary postoperatory mortality mortality after surgery. Units of measure: percentage 30 days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT00164918 - Role of Routine Nasogastric Decompression After Subtotal Gastrectomy Phase 3
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Completed NCT05088304 - GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
Active, not recruiting NCT00164892 - Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Phase 3
Active, not recruiting NCT00165048 - Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Phase 3
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03468712 - Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01614522 - A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 Phase 2
Completed NCT02374255 - Improving Goals of Care Discussion in Advanced Cancer Patients N/A
Recruiting NCT05804331 - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Recruiting NCT04270890 - Investigation of an Abdominal Compression Device N/A
Recruiting NCT02486601 - NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma Phase 2
Not yet recruiting NCT05041335 - Wet Heparinized Suction for Abdominal Cancer N/A
Completed NCT03541629 - Audit of the Spanish EURECCA Esophagogastric Cancer Registry
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Completed NCT05688761 - Nordic Gastric and Esophageal Tumor Study